Chen Chengqian, Zhong Wentao, Zheng Hao, Dai Gaoying, Zhao Wei, Wang Yushi, Dong Qi, Shen Botao
Department of Cardiology Center, The First Hospital of Jilin University, Changchun, China.
Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, China.
Front Cardiovasc Med. 2024 Jul 9;11:1417593. doi: 10.3389/fcvm.2024.1417593. eCollection 2024.
Uromodulin, also referred to as Tamm Horsfall protein (THP), is a renal protein exclusively synthesized by the kidneys and represents the predominant urinary protein under normal physiological conditions. It assumes a pivotal role within the renal system, contributing not only to ion transport and immune modulation but also serving as a critical factor in the prevention of urinary tract infections and kidney stone formation. Emerging evidence indicates that uromodulin may serve as a potential biomarker extending beyond renal function. Recent clinical investigations and Mendelian randomization studies have unveiled a discernible association between urinary regulatory protein levels and cardiovascular events and mortality. This review primarily delineates the intricate relationship between uromodulin and cardiovascular disease, elucidates its predictive utility as a novel biomarker for cardiovascular events, and delves into its involvement in various physiological and pathophysiological facets of the cardiovascular system, incorporating recent advancements in corresponding genetics.
尿调节蛋白,也被称为Tamm-Horsfall蛋白(THP),是一种仅由肾脏合成的肾蛋白,在正常生理条件下是主要的尿蛋白。它在肾脏系统中发挥着关键作用,不仅有助于离子转运和免疫调节,还作为预防尿路感染和肾结石形成的关键因素。新出现的证据表明,尿调节蛋白可能作为一种超越肾功能的潜在生物标志物。最近的临床研究和孟德尔随机化研究揭示了尿调节蛋白水平与心血管事件及死亡率之间存在明显关联。本综述主要阐述尿调节蛋白与心血管疾病之间的复杂关系,阐明其作为心血管事件新型生物标志物的预测效用,并深入探讨其在心血管系统各种生理和病理生理方面的作用,同时纳入了相应遗传学的最新进展。